Transcript Prostate Cancer Studies - PC-REF

Prostate Cancer Studies
Mohamed Bidair, M.D.
Diplomate, American Board of Urology
Alvarado La Mesa Urology
f Medical Associates
Prostate Cancer Research and Education
Foundation
Featured Speaker Series
December 13, 2003
Prostate Cancer Studies

An investigational selective endothelin
receptor antagonist, being developed for the
treatment of prostate cancer. These patients
must be status-post prostatectomy, hormone
naïve, with rising PSA.
Prostate Cancer Studies

Open-Label Leuprolide formulation for
patients with prostate cancer in need of
chemical castration. A percentage of
patients currently on a leuprolide castration
regime can be entered in the study if dosing
schedule isn’t interupted
Prostate Cancer Studies

A 3 Month Open Label study for patients
with advanced prostate cancer curently
receiving Lupron or Zoladex versus a new
investigational Leuprolide. The study is
looking to compare the degree of
testosterone suppression, Quality of Life
and safety and tolerability between Lupron,
Zoladex, and a new agent.
Prostate Cancer Studies

An intravenous bisphosphonate to study the
efficacy on the bone mineral density in
patients undergoing androgen deprivation
therapy for < 1 year. No distant metastasis
is required to enter study.
Prostate Cancer Studies

A new oral bisphosphonate to prevent
skeletal complications in metatastic prostate
cancer patients commencing androgen
deprivation therapy.
Prostate Cancer Studies

A new investigational drug, a SERM, to
prevent androgen deprivation induced
osteoporosis. This compund may also have
a direct inhibitory effect on cancer cells, and
ameliorate gynecomastia and hot flashes.
These patients must have received LHRH
treatment > 2 years, PSA < 4, and do not
take anti-androgens (Casodex, Eulexin)
Prostate Cancer Studies

An agent being evaluated to reduce the need
for transfusion in anemic patients with nonmyeloid cancer who are not receiving
chemotherapy or radiotherapy.
Prostate Cancer
Prevention Study

A study to assess the efficacy and safety of AlphaReductase Inhibitor. A 4 year study to reduce the
risk of biopsy detectable prostate cancer. Looking
for males 50-75 with only one negative biopsy
within 6 months of study enrollment. PSA must
be between 2.5-10 for males ages 50-60 and
between 3-10 for men > 60 years. Must not have
had more than one prostate biopsy or any other
prostate surgical procedures.